Note 17 – Warrants
|9 Months Ended|
Jan. 31, 2023
|Note 17 Warrants|
|Note 17 – Warrants||
Note 17 – Warrants
The company issued five-year warrants in connection with two convertible note financings. The warrants have an initial exercise price of $1.50 which may be reduced to a 25% discount of the price per share of Common Stock offered in a future qualified offering. The warrants were valued using the multinominal lattice model and are considered derivative liabilities under ASC 815-40. The value of the warrants was included in the determination of the initial accounting for each financing including the calculation of the derivative liability and related expense.
A summary of the warrants issued and their fair values were:
In March and April 2021, we received $201,249 related to the exercise of of the warrants. Since these exercises resulted in the elimination of the derivative liability in the warrants, the derivative liability was reduced by $694,305 with a corresponding increase in additional paid in capital. In June 2021, we received $99,999 in connection with the exercise of warrants which resulted in the elimination of $163,141 of the derivative liability in the warrants.
In May 2021, the Company issued warrants to purchase 5.00.shares of common stock to the placement agent of its common stock offering. The warrants have a five-year term and an exercise price of $
In July 2021, the Company issued warrants to purchase shares of common stock to the placement agent of its common stock offering. The warrants have a five-year term and an exercise price of $5.625.
The following table presents the range of assumptions used to estimate the fair values of warrants granted during the nine months ended January 31:
The following table summarizes the changes in warrants outstanding since April 30, 2021.